|
Teleconference by LBBC for Her2 Women
 2/18/09
Dear Vicki, Lowering Risk of Recurrence
Women who switched to an aromatase inhibitor (AI) after two to three years of tamoxifen lowered their risk of recurrence, results of a recent analysis indicate.
Presented at the 31st Annual San Antonio Breast Cancer Symposium, these results apply to postmenopausal women with early-stage, estrogen receptor-positive (ER+) breast cancer. This study was a meta-analysis, when researchers pool data from a number of similar studies to look for a stronger finding of the impact of the treatment than any single study could find alone.
Visit our Web Site to learn more.
Lymphedema Teleconference on Friday
It’s not too late to registerfor our next national teleconference, Understanding Lymphedema, from 12:00 p.m. to 1:30 p.m. Eastern Standard Time (EST) this Friday, February 20.
 Andrea L. Cheville, MD, MSCE, of the Mayo Clinic, will provide an overview of lymphedema. Whether you already have lymphedema or have concerns about developing it, at this teleconference you will learn: - Causes and methods of prevention
- The importance of early detection
- Medical and holistic treatment methods
- Impact of the condition on your quality of life
Visit our Web site for more information.
HER2 Positive Advanced Breast Cancer A new medicine that includes trastuzumab (brand name: Herceptin) shows promise for HER2 positive advanced (metastatic) breast cancer that progresses after treatment with trastuzumab and chemotherapy, results of an interim analysis indicate.
The results of this phase II study were presented at the 31st Annual San Antonio Breast Cancer Symposium in December 2008. The initial findings from this trial suggest that researchers may have found another possible option for treatment-resistant HER2 positive metastatic breast cancer.
Visit our Web Site to learn more about this study.
__________________
Diagnosed 12/03 at age 53
1.5cm tumor, ER-PR-, Her2 3+(rt side)
Stage 1B, Three negative nodes from Sentinel Node Biopsy
Paget's of the nipple, Infiltrating Ductal Carcinoma and DCIS of the rt breast
Bloom-Richardson score 8/9, P53+ 60-70%, Ki-67+ 30-40%
Skin-sparing mastectomy with immediate lat-flap reconstruction and saline implants, 1/04
Chemo: FAC, five sessions every three weeks Feb.-May 04, then switched to HTC weekly for 12 weeks, June-Aug 04
Zometa every 6 months for osteopenia, started April 09
|
Linear Mode
